Blog Posts
May 29, 2024

Finding Motivation in Drug Research: An Interview with Debarati Biswas

Blog Posts
May 29, 2024

Finding Motivation in Drug Research: An Interview with Debarati Biswas

Author
Neneh Vannitamby, MD
Medical Writer

In this edition of “In the Spotlight,” we are excited to introduce Debarati Biswas, the dynamic Product Manager at LARVOL. With a lifelong fascination for drug research and a career spanning various facets of healthcare and equity research, Debarati brings a unique perspective to her role. Her journey from childhood experiences with medicine to becoming a key player in oncology at LARVOL is both inspiring and enlightening. Join us as we delve into her story, exploring her professional passions, motivations, and the unique qualities she brings to the LARVOL team.

Debarati Biswas, Product Manager LARVOL PULSE

Could you briefly introduce yourself and describe your role at LARVOL?

From a young age, I've been exposed to the medical field having been surrounded by illnesses and hospitalizations, sparking a lifelong fascination with medicine. While I was never drawn to becoming a doctor, my passion for drug research and data analysis guided my career path. At LARVOL, I serve as the Product Manager for LARVOL PULSE, where I stay abreast of the latest developments in cancer treatment and other drug therapies.

Every person's journey is unique. Can you share with us the story of how you landed in the field of oncology and at LARVOL specifically?

My journey into healthcare began with a profound interest in drug research, which eventually led me to analyze healthcare stocks at an equity research firm. In search of a more adaptable work environment, I explored remote opportunities and discovered LARVOL—a place that seemed tailor-made for my skills and interests.

What do you enjoy most about your role at LARVOL and how has it impacted your professional journey?

Being part of LARVOL’s diverse team is amazing! We have a respectful work environment where everyone brings their unique perspective to the table. It’s like working with a pack of high-performing tigers – we’re fast and on a mission. Nearly a decade of remote work have sharpened my ability to effectively communicate, honed my ability to read situations accurately and develop into a versatile professional. 

In an industry as fast-paced as ours, it's important to have strong motivation. What personally motivates you in your role at LARVOL, and how do you keep that motivation alive in the face of challenges?

The chance to delve into drug research is inherently motivating. The constant learning keeps me engaged and happy, like a daily dose of dopamine.  When faced with challenges, I focus on what I can control. Work itself is a form of therapy for me, allowing me to stay present and avoid getting overwhelmed.

At LARVOL, we know the importance of work-life balance. Outside of your professional role, what unique hobby or interest might surprise your colleagues at LARVOL?

Outside of work, one of my lesser-known skills is handwriting analysis. I have a knack of understanding people through the way they write, which often surprises those who know me professionally.

It’s clear that Debarati is not only a dedicated professional but also a passionate individual whose journey continues to inspire. Her commitment to drug research and her ability to balance professional excellence with personal interests make her a valued member of the LARVOL team.

We hope Debarati’s story encourages you to pursue your passions and stay motivated in the face of challenges. Stay tuned for more inspiring stories from our remarkable team members in future editions of “In the Spotlight.”

Download attached file
Not rated
Allison Betof Warner, MD, PhD (she/her) 4
3743
Manhattan, NY
November 10, 2022

79% had reduction in disease. ORR 31%. Many responses deepen over time.

Not rated
Allison Betof Warner, MD, PhD (she/her) 3
3743
Manhattan, NY
November 10, 2022

Median DOR not yet reached. Median OS 13.9 mo. 12 mo OS was 54%. As typical with immunotherapy, we see a nice tail on the curve. #TIL#SITC22

Positive
Alex Shoushtari, MD
2253
New York, USA
November 10, 2022

Important work on efficacy of TIL therapy lifileucel in PD-1 resistant #melanoma being presented at #SITC22. Pretty good durability for this heavy lift of a treatment.

Not rated
Allison Betof Warner, MD, PhD (she/her) 2
3743
Manhattan, NY
November 10, 2022

Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.

Positive
Hussein Tawbi, MD, PhD
1685
Houston, TX
November 10, 2022

Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated

Positive
Allison Betof Warner, MD, PhD (she/her) 1
3744
Manhattan, NY
November 10, 2022

Where does this leave us with #TIL therapy for #melanoma? IMO, this response rate/durability justifies accelerated approval. Pts with PD-1 refractory melanoma need options. It’s FAR from a perfect tx but provides meaningful clinical benefit. What say you melanoma Twitterverse?

Not Rated
Sumanta K. Pal, MD, FASCO
15083 Followers
Los Angeles, CA
November 8, 2022

Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A

not rated
Shilpa Gupta
5095 Followers
Cleveland, OH
November 8, 2022
Not Rated
Tian Zhang, MD, MHS
6463 Followers
Dallas, TX
November 8, 2022

CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe

Not Rated
Moshe Ornstein MD
1930 Followers
Cleveland, OH
November 8, 2022

Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt

Not Rated
Shuchi Gulati MD
12476 Followers
Seattle, WA
November 8, 2022

Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7

Not Rated
Petros Grivas
12476 Followers
Seattle, WA
November 8, 2022

Subscribe to our newsletter

Sign up for our newsletter to get the latest news, updates and high-impact data delivered directly to your inbox.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.